Alnylam Pharmaceuticals Inc

Financials

Flusso di cassa derivante dalle attività operative -94.66 M-118.31 M153.73 M325.11 M163.56 M 524.08 M Flussi di cassa derivanti dalle attività di investimento -52.91 M113.77 M-141.38 M501.11 M-37.17 M 436.33 M Liquidità derivante dalle attività di finanziamento 31 M44.08 M53.76 M-448.35 M45.32 M -305.19 M Liquidità libera -103.76 M-127.28 M139.44 M312.97 M140.26 M 465.38 M

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

ALNY

Financials

Alnylam Pharmaceuticals Inc

Notizie

Leaderboard Trimmed, But Cloudflare, Caterpillar Among 5 Stocks To Watch

Alnylam presenta dati cardiovascolari alla conferenza ACC

Repligen (RGEN) Down 13.5% Since Last Earnings Report: Can It Rebound?

H.C. Wainwright conferma rating buy su Alnylam con target $510

Stifel conferma rating Buy su Alnylam, target a $444

Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Progress and Strategy in Transforming ATTR Amyloidosis Care and Expanding TTR Franchise Transcript

Morgan Stanley conferma rating Equalweight su Alnylam a $360

BofA Securities conferma target di $460 per le azioni Alnylam

Alnylam collabora con Viz.ai e AHA per la diagnosi di ATTR-CM

Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?

Jefferies declassa Alnylam per preoccupazioni sulla valutazione

Jefferies downgrades Alnylam stock rating on valuation concerns